MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The res ...

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The re ...

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that it will participate in the Virtual Life Sciences Investor Forum taking place June 20, 2024. Details for the Company's participation:  Fireside Chat Date:Fireside Chat Time:Thursday, June 20, 2024 ...

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in Apri ...

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in Apr ...

Longeveron (NASDAQ:LGVN) stock continues to rally on Thursday as investors celebrate positive trial news from the clinical-stage biotechnology company.The big news that boosted shares of LGVN stock higher was investigator data from a Phase 2 trial of Lomocel-B. This is the company’s treatment candidate for patients suffering from hypoplastic left heart syndrome (HLHS).The Phase 2 trial of Lomocel-B is still ongoing and the investigator meeting was positive. That’s a win for the company and investors in LGVN ...

The clinical-stage biotech market is as vast as it is complicated. Companies operating in this space are wide-ranging in the illnesses they look to treat. But when they get it right, these stocks can move in a big way. Today, Longeveron (NASDAQ:LGVN) is the biotech stock getting significant attention, as LGVN stock surged more than 120% in today’s session.In fact, as I’m writing this, LGVN stock has already more than doubled on the day. Indeed, as is the case with most such moves in the biotech sector, inve ...

With current HLHS treatment, only 50-60% of infants survive to adolescenceIn ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B™ compared to approximate 20% mortality rate observed from historical control dataELPIS II Phase 2b clinical trial on track for completing enrollment by end of 2024Multiple nationally recognized children's treatment centers participating in ELPIS II MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- Longeveron I ...

MIAMI, June 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024. Details for the Company's presentation:  Date:Wednesday, June 12, 2024 Time:1:45 p.m. ET The webcast for this conference presentation may be accessed at the "Events and Presentations" section of the Company's website. A replay of the webcast will be av ...

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics MIAMI, June 03, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the launch of its contract development and manufacturing business at ...